About Albireo Pharma
Albireo Pharma is a company based in Goteborg (Sweden) founded in 2008 was acquired by Ipsen in January 2023.. Albireo Pharma has raised $40 million across 1 funding round from investors including TPG, Ipsen and TVM Capital Life Science. Albireo Pharma offers products and services including Oncology Medicines, Rare Disease Therapies, and Neuroscience Products. Albireo Pharma operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Goteborg, Sweden
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Albireo Pharma, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Albireo Pharma
Albireo Pharma offers a comprehensive portfolio of products and services, including Oncology Medicines, Rare Disease Therapies, and Neuroscience Products. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatments for cancers like neuroendocrine tumors
Medicines for rare conditions such as liver diseases
Solutions for debilitating neurological conditions
Unlock access to complete
Unlock access to complete
Funding Insights of Albireo Pharma
Albireo Pharma has successfully raised a total of $40M through 1 strategic funding round. The most recent funding activity was a Series A round of $40 million completed in February 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $40.0M
-
First Round
First Round
(01 Feb 2008)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2008 | Amount | Series A - Albireo Pharma | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Albireo Pharma
Albireo Pharma has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include TPG, Ipsen and TVM Capital Life Science. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Capital is invested in life science innovations for healthcare transformation.
|
Founded Year | Domain | Location | |
|
Fund of funds focused on pre-seed and seed-stage companies
|
Founded Year | Domain | Location | |
|
Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Albireo Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Albireo Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Albireo Pharma Comparisons
Competitors of Albireo Pharma
Albireo Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Albireo Pharma
Frequently Asked Questions about Albireo Pharma
When was Albireo Pharma founded?
Albireo Pharma was founded in 2008.
Where is Albireo Pharma located?
Albireo Pharma is headquartered in Goteborg, Sweden. It is registered at Goteborg, Vastra Gotaland, Sweden.
Is Albireo Pharma a funded company?
Albireo Pharma is a funded company, having raised a total of $40M across 1 funding round to date. The company's 1st funding round was a Series A of $40M, raised on Feb 01, 2008.
What does Albireo Pharma do?
Albireo Pharma was founded in 2008 in Gothenburg, Sweden, and operates in the biopharmaceutical sector focused on liver and gastrointestinal disorders. Bile acid modulators are developed to address orphan pediatric liver diseases and other related conditions. The clinical pipeline includes elobixibat and Bylvay, which are potent ileal bile acid transporters, as well as A4250, an inhibitor for cholestatic liver disease. Operations emphasize treatment options for these specialized areas.
Who are the top competitors of Albireo Pharma?
Albireo Pharma's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Albireo Pharma offer?
Albireo Pharma offers Oncology Medicines, Rare Disease Therapies, and Neuroscience Products.
Who are Albireo Pharma's investors?
Albireo Pharma has 3 investors. Key investors include TPG, Ipsen, and TVM Capital Life Science.